Thyroid hormone replacement for nephrotic syndrome patients with euthyroid sick syndrome: a meta-analysis.

Huixin Liu,Wenjun Yan,Gaosi Xu
DOI: https://doi.org/10.3109/0886022X.2014.949559
IF: 3.222
2014-01-01
Renal Failure
Abstract:Objective: To assess the efficacy of thyroid hormone replacement therapy for nephrotic syndrome (NS) patients associated with euthyroid sick syndrome (ESS). Materials and methods: The Cochrane library, ISI, Ovid, PubMed, Chinese Biomedicine Database were searched, and reference list of relevant articles were selected. Randomized controlled trials (RCTs) or quasi-RCTs with thyroid hormone replacement on NS patients associated with ESS were included in this analysis. Results: Six trials (329 participants) were included. Meta-analysis showed that thyroid hormone replacement therapy can significantly increase the completely remission rate [OR = 3.04, 95% confidence interval (CI): 3.04-1.88, p<0.00001] and total response rate (OR = 4.63, 95% CI: 2.46-8.71, p<0.00001) of NS patients associated with ESS. No side effect was observed during the follow-up period. There was no obvious publication bias in the mete-analysis studies. Conclusions: Thyroid hormone replacement therapy significantly increases the remission of ESS in patients with NS.
What problem does this paper attempt to address?